EGFR and non-small cell lung carcinoma: However, patients with advanced NSCLC harboring EGFR‐activating mutations develop progressive disease (PD) in a median response period of 10–12 months after taking first‐generation TKIs, such as erlotinib and gefitinib (Lin et al., 2014; O'Kane et al., 2018; Tan et al., 2018; Wu and Shih, 2018).